Group 1 - Encore Medical plans to issue 3 million shares at a price of $5 per share, aiming to raise $15 million through its IPO [1] - The company is headquartered in Eagan, Minnesota, and specializes in developing and manufacturing interatrial septal occluders for repairing heart defects such as patent foramen ovale (PFO) [1] - Encore Medical's device has been approved for sale in the European Union, but it has not yet received regulatory approval for sale in the United States; however, it has FDA approval to conduct trials for market clearance [1] Group 2 - The company's projected revenue for the 12 months ending September 30, 2025, is $2 million [1]

TABLE OF CONTENTS REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 30, 2025 Registration No. 333-290244 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENCORE MEDICAL, INC. (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Classification Code Number) Minnesota (State or other jurisdiction of inc ...

Group 1 - The article discusses the services provided by IPO Edge, which includes actionable information on growth stocks, first-look IPO filings, previews of upcoming IPOs, an IPO calendar, a database of U.S. IPOs, and a comprehensive guide to IPO investing [1]

TABLE OF CONTENTS REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 12, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENCORE MEDICAL, INC. (Exact name of registrant as specified in its charter) 3841 Minnesota (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Numb ...